# Pharmacosmos A/S

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/pharmacosmos-as
Canonical HTML page: https://getbiobrief.com/entity/pharmacosmos-as

## Timeline

- **2026-07-21**: Partnership Announcement — Menarini Asia-Pacific and Pharmacosmos announce exclusive licensing and distribution agreement for Cosela in 11 APAC markets.

## Recent coverage (1 stories)

### Trilaciclib Partnership Expands Myeloprotection to 11 Asia-Pacific Markets
2026-07-27 11:19:11 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Pharmacosmos partners with Menarini to commercialize trilaciclib (Cosela), the first FDA-approved prophylactic therapy for chemotherapy-induced myelosuppression, across 11 Asia-Pacific markets, marking a significant geographic expansion for the first-in-class agent.
Full story: https://getbiobrief.com/story/pharmacosmos-menarini-trilaciclib-asian-expansion-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.